Thumbnail Image
Publication

ENGOT-ov-6/TRINOVA-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Marth, C
; 
Vergote, I
; 
Scambia, G
; 
Oberaigner, W
; 
Clamp, Andrew R
; 
Berger, R
; 
Kurzeder, C
; 
Colombo, N
; 
Vuylsteke, P
; 
Lorusso, D
... show 10 more
Citations
Altmetric:
Abstract
Trebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of angiopoietin-1/2 to the receptor tyrosine kinase Tie2. This randomised, double-blind, placebo-controlled phase 3 study evaluated whether trebananib plus pegylated liposomal doxorubicin (PLD) improved progression-free survival (PFS) in patients with recurrent epithelial ovarian cancer.
Authors
Marth, C
Vergote, I
Scambia, G
Oberaigner, W
Clamp, Andrew R
Berger, R
Kurzeder, C
Colombo, N
Vuylsteke, P
Lorusso, D
Hall, M
Renard, V
Pignata, S
Kristeleit, R
Altintas, S
Rustin, G
Wenham, R
Mirza, M
Fong, P
Oza, A
Monk, B
Ma, H
Vogl, F
Bach, B
Affiliation
AGO-Austria and Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
Description
Date
2017-01
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
ENGOT-ov-6/TRINOVA-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. 2017, 70:111-121 Eur J Cancer
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620130
Embedded videos